# A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

> **NCT02548078** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 600 (actual)

## Conditions studied

- Virus Diseases

## Interventions

- **BIOLOGICAL:** GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
- **BIOLOGICAL:** Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine

## Key facts

- **NCT ID:** NCT02548078
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-09
- **Primary completion:** 2017-05-15
- **Final completion:** 2017-05-15
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2018-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02548078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02548078, "A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02548078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*